CIT:GETTEXCintas Corporation Analysis
Data as of 2026-05-25 - not real-time
$125.09
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Citi's stock trades at $125.09, just below its 20‑day SMA of $125.94 but comfortably above the 50‑day ($121.71) and 200‑day ($109.76) averages, signaling a lingering bullish bias. The RSI sits near 51, indicating neutral momentum, while the MACD histogram is negative and the signal line is bearish, suggesting short‑term pressure. Volume has been decreasing and 30‑day volatility is elevated at ~24%, compounded by a high beta of ~1.45, which together raise the near‑term risk profile.
Fundamentally, the bank delivers strong top‑line growth (~16% revenue increase) and robust profitability (34% operating margin, 20% profit margin). Forward earnings are projected to rise sharply, with EPS moving from $8.09 to $12.53 and a forward P/E of just 9.98 versus an industry average of 16.75, indicating attractive valuation. The price‑to‑book of 1.11 and a dividend yield of 1.9% with a 29% payout ratio point to a sustainable income component.
Valuation metrics suggest the stock is undervalued, with analysts averaging a target price near $147 and an implied upside of roughly 17%. The combination of growth prospects, reasonable dividend, and a solid capital cushion (cash exceeding debt) supports a longer‑term buy case, while short‑term technical signals advise a cautious hold.
Fundamentally, the bank delivers strong top‑line growth (~16% revenue increase) and robust profitability (34% operating margin, 20% profit margin). Forward earnings are projected to rise sharply, with EPS moving from $8.09 to $12.53 and a forward P/E of just 9.98 versus an industry average of 16.75, indicating attractive valuation. The price‑to‑book of 1.11 and a dividend yield of 1.9% with a 29% payout ratio point to a sustainable income component.
Valuation metrics suggest the stock is undervalued, with analysts averaging a target price near $147 and an implied upside of roughly 17%. The combination of growth prospects, reasonable dividend, and a solid capital cushion (cash exceeding debt) supports a longer‑term buy case, while short‑term technical signals advise a cautious hold.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD histogram indicating near‑term downside pressure
- Decreasing trading volume and high short‑term volatility
- Price hovering just below the 20‑day SMA, limiting immediate upside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong earnings growth outlook with forward EPS of $12.53
- Attractive forward P/E of 9.98 versus industry average
- Sustainable dividend yield of 1.9% with low payout ratio
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Robust global diversification reducing concentration risk
- Net cash position exceeding total debt, providing financial resilience
- Significant upside potential to the consensus target price of $147
Key Metrics & Analysis
Financial Health
Revenue Growth15.90%
Profit Margin20.36%
P/E Ratio15.5
ROE7.65%
ROA0.61%
P/B Ratio1.1
Op. Cash Flow$-30797000704
Industry P/E16.8
Technical Analysis
TrendBullish
RSI51.1
Support$119.76
Resistance$131.95
MA 20$125.94
MA 50$121.71
MA 200$109.76
MACDBearish
VolumeDecreasing
Fear & Greed Index91.8
Valuation
Target Price$146.93
Upside/Downside17.46%
GradeUndervalued
TypeBlend
Dividend Yield1.92%
Risk Assessment
Beta1.45
Volatility24.09%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.